Brazil’s medical device industry resurgent after H1’19 stagnation



According to the Brazilian Alliance of Innovative Health Industry (ABIIS), the medical device sector experienced a 2.4% year-on-year (YOY) growth during the January-September period, driven by 3.2% and 2.1% YOY expansions in domestic production and imports respectively. This performance is a signal of recovery after a period of stagnation during the first half of 2019, and is due to an increase in the number of clinics and other health institutions.

However, exports dropped 1.6% YOY in the nine-month period, to USD 456 million. Compounded with USD 3.4 billion in imports, this resulted in a negative trade balance of USD 2.9 billion.

Reference:

Recent news
Chile’s Ministry of Health (MINSAL) this week announced measures against gender and age inequalities regarding Welfare Health Institutions (ISAPREs) fees.
Brazil-based Biolab, the leading seller of cardiology medicines in the Brazilian market, has signed an agreement with France-based Quantum Genomics to partner on the development, production, and commercialization in Latin America of a novel treatment for hypertension.
According to preliminary data from Mexico’s 2018 National Health and Nutrition Survey (ENSANUT), chronic diseases have continued to increase in the country since the previous survey in 2012.
Shandong province is set to scrap mark-ups on medical consumables at public medical institutions, according to a document released by the province.
US-based AbbVie’s Bruton’s tyrosine kinase (BTK) inhibitor ABBV-105 and Janus kinase 1 (JAK1) inhibitor upadacitinib (trade name: Rinvoq) have both won clinical trial approvals from the Center for Drug Evaluation (CDE).
China’s national drug use monitoring platform, online since November 25, now covers a network of 8,840 medical institutions and is handling an average 600,000 person visits daily, according to the National Healthcare Commission (NHC).
US-based biotech Amgen (Nasdaq.AMGN) trumpeted a new indication approval for its PCSK9 inhibitor Repatha (evolocumab) in China.
Analytics Snapshot


Analytics Snapshot